Galectin Therapeutics Inc
GALT3.590USD
-0.060-1.64%
收盘 08/04, 16:00（美东）报价延迟15分钟
227.22M总市值
亏损市盈率 TTM
关于 Galectin Therapeutics Inc 公司
Galectin Therapeutics, Inc. 是一家临床阶段的生物制药公司，致力于开发新型疗法，改善慢性肝病和癌症患者的生活。该公司的候选药物基于其针对半乳糖凝集素蛋白的方法，半乳糖凝集素蛋白是生物和病理功能的关键介质。该公司的主要药物 belapectin 是一种基于碳水化合物的药物，可抑制半乳糖凝集素-3 蛋白，该蛋白直接参与多种炎症、纤维化和恶性疾病，美国食品药品管理局已授予其快速通道资格。主要开发项目是代谢功能障碍相关脂肪性肝炎 (MASH，以前称为非酒精性脂肪性肝炎或 NASH) 伴有肝硬化，这是 MASH 相关纤维化的最晚期形式。该公司的其他开发项目是治疗晚期头颈癌和其他恶性肿瘤的联合免疫疗法。
公司简介
公司代码GALT
公司名称Galectin Therapeutics Inc
上市日期Sep 04, 2002
CEOMr. Joel Lewis, CPA
员工数量15
证券类型Ordinary Share
年结日Sep 04
公司地址Suite 240
城市NORCROSS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编30071
电话16786203186
网址https://galectintherapeutics.com/
公司代码GALT
上市日期Sep 04, 2002
CEOMr. Joel Lewis, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Dr. Khurram Jamil
Dr. Khurram Jamil
Chief Medical Officer
Chief Medical Officer
60.00K
-9.57%
Dr. Harold H. Shlevin, M.D., Ph.D.
Dr. Harold H. Shlevin, M.D., Ph.D.
Independent Director
Independent Director
15.21K
--
Dr. Benjamin S. Carson, Sr.
Dr. Benjamin S. Carson, Sr.
Director
Director
--
--
Ms. Elissa J. Schwartz, Ph.D.
Ms. Elissa J. Schwartz, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
持股股东
持股股东
占比
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
股东类型
持股股东
占比
Individual Investor
21.60%
Investment Advisor
12.44%
Corporation
9.36%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.20%
Bank and Trust
0.17%
Hedge Fund
0.03%
Pension Fund
0.02%
Venture Capital
0.02%
Other
53.56%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
173
29.39M
46.46%
-903.45K
2025Q1
175
29.27M
46.24%
-1.01M
2024Q4
167
29.61M
47.52%
-69.18K
2024Q3
148
29.06M
46.85%
-523.51K
2024Q2
138
28.80M
46.46%
+1.25M
2024Q1
119
26.89M
43.43%
-139.12K
2023Q4
120
26.57M
43.67%
-339.82K
2023Q3
131
28.59M
47.99%
+3.27M
2023Q2
140
24.60M
41.36%
-1.20M
2023Q1
165
24.44M
41.11%
-1.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Uihlein (Richard E)
10.34M
16.34%
--
--
Feb 28, 2025
10X Fund, L.P.
5.92M
9.36%
--
--
Feb 28, 2025
The Vanguard Group, Inc.
2.19M
3.46%
+54.90K
+2.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.34M
2.11%
-201.81K
-13.12%
Mar 31, 2025
Osaic Holdings, Inc.
1.22M
1.93%
+42.88K
+3.63%
Mar 31, 2025
Czirr (James C)
1.09M
1.72%
+323.13K
+42.20%
Jun 06, 2025
Lewis (Joel)
930.30K
1.47%
-56.42K
-5.72%
Mar 03, 2025
Geode Capital Management, L.L.C.
852.71K
1.35%
-17.88K
-2.05%
Mar 31, 2025
Eldred (Kary N.)
499.63K
0.79%
--
--
Feb 28, 2025
Freeman (Kevin D)
462.01K
0.73%
-220.37K
-32.29%
Feb 28, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
占比0.02%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Growth ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
